Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Recent progress in the development of small molecule Nrf2 activators: a patent review (2017-present)
Hai-Shan Zhou, Yan Wang, Qidong You, et al.
Expert Opinion on Therapeutic Patents (2020) Vol. 30, Iss. 3, pp. 209-225
Closed Access | Times Cited: 42

Showing 1-25 of 42 citing articles:

<p>Reactive Oxygen Species: Drivers of Physiological and Pathological Processes</p>
Javier Checa, Josep M. Aran
Journal of Inflammation Research (2020) Vol. Volume 13, pp. 1057-1073
Open Access | Times Cited: 613
Podocyte Injury in Diabetic Kidney Disease: A Focus on Mitochondrial Dysfunction
Simeng Liu, Yanggang Yuan, Yi Xue, et al.
Frontiers in Cell and Developmental Biology (2022) Vol. 10
Open Access | Times Cited: 41
Activation of Nrf2 pathway as a protective mechanism against oxidative stress-induced diseases: Potential of astaxanthin
Osman N. Kanwugu, Т. В. Глухарева
Archives of Biochemistry and Biophysics (2023) Vol. 741, pp. 109601-109601
Closed Access | Times Cited: 25
Natural products as non-covalent and covalent modulators of the KEAP1/NRF2 pathway exerting antioxidant effects
Giulia Culletta, Brigitta Buttari, Marzia Arese, et al.
European Journal of Medicinal Chemistry (2024) Vol. 270, pp. 116355-116355
Closed Access | Times Cited: 13
Recent progress in Keap1-Nrf2 protein-protein interaction inhibitors
Yi Mou, Shuai Wen, Yuxiu Li, et al.
European Journal of Medicinal Chemistry (2020) Vol. 202, pp. 112532-112532
Closed Access | Times Cited: 68
Emerging Substrate Proteins of Kelch-like ECH Associated Protein 1 (Keap1) and Potential Challenges for the Development of Small-Molecule Inhibitors of the Keap1-Nuclear Factor Erythroid 2-Related Factor 2 (Nrf2) Protein–Protein Interaction
Yong Zhang, Zeyu Shi, Yujun Zhou, et al.
Journal of Medicinal Chemistry (2020) Vol. 63, Iss. 15, pp. 7986-8002
Closed Access | Times Cited: 50
Development of Noncovalent Small-Molecule Keap1-Nrf2 Inhibitors by Fragment-Based Drug Discovery
Dilip Narayanan, Kim T. Tran, Jakob S. Pallesen, et al.
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 21, pp. 14481-14526
Closed Access | Times Cited: 29
Selective inhibition of cullin 3 neddylation through covalent targeting DCN1 protects mice from acetaminophen-induced liver toxicity
Haibin Zhou, Jianfeng Lü, Krishnapriya Chinnaswamy, et al.
Nature Communications (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 33
NRF2 is a critical regulator and therapeutic target of metal implant particle-incurred bone damage
Jian Dong, Lijun Zhang, Binjia Ruan, et al.
Biomaterials (2022) Vol. 288, pp. 121742-121742
Closed Access | Times Cited: 25
An updated patent review of Nrf2 activators (2020-present)
Ziquan Zhao, Ruitian Dong, Keni Cui, et al.
Expert Opinion on Therapeutic Patents (2023) Vol. 33, Iss. 1, pp. 29-49
Closed Access | Times Cited: 15
5-(3-(N-(Carboxymethyl)naphthalene-2-sulfonamido)phenyl)-1-ethyl-1H-pyrrole-2-carboxylic acid as a Keap1–Nrf2 inhibitor for cerebral ischemia/reperfusion injury treatment
Nanjia Cairang, Yanran Wu, Shumeng Zhi, et al.
RSC Advances (2025) Vol. 15, Iss. 2, pp. 1052-1059
Open Access
Mechanisms Associated With Renal Injury in Hyperuricemia and Strategies for the Development of Natural Active Substances
Wanping Lv, Huixiang Chen, Pan Zhou, et al.
International Journal of Rheumatic Diseases (2025) Vol. 28, Iss. 2
Closed Access
Patenting perspective on Keap1 inhibitors (2019-2024)
Yue Luo, Wenlong Yang, Yuan Zhang, et al.
Expert Opinion on Therapeutic Patents (2025)
Closed Access
The role of NRF2 function and regulation in atherosclerosis: an update
Siarhei A. Dabravolski, Alexey V. Churov, Dmitry F. Beloyartsev, et al.
Molecular and Cellular Biochemistry (2025)
Closed Access
The Nrf2-Keap1/ARE signaling pathway in aquatic animals
Dan‐Dan Bian, Xue Zhang, Xi-Rong Zhu, et al.
International Journal of Biological Macromolecules (2025), pp. 142595-142595
Closed Access
Design, Synthesis, and Structure–Activity Relationships of Indoline-Based Kelch-like ECH-Associated Protein 1-Nuclear Factor (Erythroid-Derived 2)-Like 2 (Keap1-Nrf2) Protein–Protein Interaction Inhibitors
Hai-Shan Zhou, Lv-Bin Hu, Han Zhang, et al.
Journal of Medicinal Chemistry (2020) Vol. 63, Iss. 19, pp. 11149-11168
Closed Access | Times Cited: 38
A hydrogen peroxide responsive prodrug of Keap1-Nrf2 inhibitor for improving oral absorption and selective activation in inflammatory conditions
Mengchen Lu, Xian Zhang, Jing Zhao, et al.
Redox Biology (2020) Vol. 34, pp. 101565-101565
Open Access | Times Cited: 33
Oxidative stress in genetically triggered thoracic aortic aneurysm: role in pathogenesis and therapeutic opportunities
Stefanie S. Portelli, Brett D. Hambly, Richmond Jeremy, et al.
Redox Report (2021) Vol. 26, Iss. 1, pp. 45-52
Open Access | Times Cited: 31
Beyond direct Nrf2 activation; reinvestigating 1,2,4-oxadiazole scaffold as a master key unlocking the antioxidant cellular machinery for cancer therapy
Mohammed Salah Ayoup, Marwa M. Abu‐Serie, Hamida Abdel‐Hamid, et al.
European Journal of Medicinal Chemistry (2021) Vol. 220, pp. 113475-113475
Closed Access | Times Cited: 28
The Multifaceted Neurotoxicity of Astrocytes in Ageing and Age-Related Neurodegenerative Diseases: A Translational Perspective
David Bouvier, Sonja Fixemer, Tony Heurtaux, et al.
Frontiers in Physiology (2022) Vol. 13
Open Access | Times Cited: 22
Crystallography-Guided Optimizations of the Keap1–Nrf2 Inhibitors on the Solvent Exposed Region: From Symmetric to Asymmetric Naphthalenesulfonamides
Guodong Liu, Ruilin Hou, Lijuan Xu, et al.
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 12, pp. 8289-8302
Closed Access | Times Cited: 20
Design and characterization of a heterobifunctional degrader of KEAP1
Hao Chen, Nghi Nguyen, Charlene M. Magtoto, et al.
Redox Biology (2022) Vol. 59, pp. 102552-102552
Open Access | Times Cited: 20
Medicinal Chemistry Insights into the Development of Small-Molecule Kelch-Like ECH-Associated Protein 1-Nuclear Factor Erythroid 2-Related Factor 2 (Keap1–Nrf2) Protein–Protein Interaction Inhibitors
Ziquan Zhao, Ruitian Dong, Qidong You, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 14, pp. 9325-9344
Closed Access | Times Cited: 11
Discovery of 2-oxy-2-phenylacetic acid substituted naphthalene sulfonamide derivatives as potent KEAP1-NRF2 protein-protein interaction inhibitors for inflammatory conditions
Mengchen Lu, Hong-Li Shao, Tian Liu, et al.
European Journal of Medicinal Chemistry (2020) Vol. 207, pp. 112734-112734
Closed Access | Times Cited: 27
Oat polyphenol avenanthramide-2c confers protection from oxidative stress by regulating the Nrf2-ARE signaling pathway in PC12 cells
Yanan Hou, Shoujiao Peng, Zi‐Long Song, et al.
Archives of Biochemistry and Biophysics (2021) Vol. 706, pp. 108857-108857
Closed Access | Times Cited: 21
Page 1 - Next Page

Scroll to top